Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020

10/26/20

A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib BERKELEY HEIGHTS, N.J. , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

10/23/20

BERKELEY HEIGHTS, N.J. , Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum , M.D.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference

10/05/20

BERKELEY HEIGHTS, N.J. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company is scheduled to participate in a
Read more

PDF Version
Summary Toggle Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020

09/21/20

BERKELEY HEIGHTS, N.J. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data with
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results

08/12/20

- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J. , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results

08/05/20

BERKELEY HEIGHTS, N.J. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results on
Read more

PDF Version
Summary Toggle Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

07/13/20

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – -- Data builds on growing body of evidence indicating the promise of dual CDK2/9 inhibition -- BERKELEY
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results

05/12/20

- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - - Following Recent Financing Cash Runway to End of 2022 - BERKELEY HEIGHTS, N.J. , May 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results

05/05/20

BERKELEY HEIGHTS, N.J. , May 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2020 financial results on
Read more

PDF Version
Summary Toggle Cyclacel Announces Closing of $20 Million Public Offering

04/24/20

BERKELEY HEIGHTS, N.J. , April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced
Read more

PDF Version
Summary Toggle CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING

04/21/20

BERKELEY HEIGHTS, N.J. , April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of a public offering with
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease

04/20/20

-Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury- BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom , April 20, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the
Read more
Summary Toggle Cyclacel Announces Reverse Stock Split

04/14/20

BERKELEY HEIGHTS, N.J. , April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that effective at 5:00 p.m., Eastern Time
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

02/26/20

– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib -venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – – Conference Call Scheduled February 26, 2020 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J. , Feb.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results

02/19/20

BERKELEY HEIGHTS, N.J. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2019 financial
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference

02/03/20

BERKELEY HEIGHTS, N.J. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the BIO CEO &
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020

01/13/20

– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML /MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

01/06/20

BERKELEY HEIGHTS, N.J. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech
Read more

PDF Version
Summary Toggle Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

12/09/19

CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies BERKELEY HEIGHTS, N.J. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

11/13/19

– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"),
Read more

PDF Version

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter